Glucagon-like peptide 1 (GLP-1) is released during and after meals and leads to satiation and satiety [14–16], and in recent years GLP-1 analogues are increasingly being used in anti-obesity treatment because of this “acute” eating reducing effect [17]. The gene discussed is GCG; the disease is Obesity.